Lunai Bioworks Inc.: requests Nasdaq suspend trading

What happened Lunai Bioworks Inc. reported that on Oct 9, 2026 it submitted a formal request to The Nasdaq Stock Market LLC asking Nasdaq to immediately suspend trading in the company’s common stock while Nasdaq, FINRA and other authorities assess trading records described in the company’s submission. The records concern trading activity that is the subject of the company’s pending litigation, Lunai Bioworks, Inc. v. Seven Points Capital LLC et al., Case No. 1:26-cv-00549-CFC, and are described in the company’s Second Amended Complaint filed on Aug 26, 2026. The filing states the company has submitted the request but has not received a decision from Nasdaq.

Key details

• request submitted on Oct 9, 2026 to Nasdaq MarketWatch asking for immediate suspension or other protective action.
• litigation referenced: Lunai Bioworks, Inc. v. Seven Points Capital LLC et al., Case No. 1:26-cv-00549-CFC.
• Second Amended Complaint filed on Aug 26, 2026; records were obtained through court-ordered discovery.
• filing cites trading records showing "substantial short selling, locate deficiencies, concentrated failures to deliver" and asks Nasdaq to review whether continued trading is consistent with a fair and orderly market.

Why it may matter The company reported Item 8.01 (other events) and described its request that Nasdaq consider suspension or other protective action while regulators review trading records tied to pending litigation. The filing also states the litigation remains pending and contains forward-looking statements about the request and litigation. This filing does not show why the insider traded or why the company acted.